At the conclusion of the inspection, the FDA issued a Form 483, outlining eight observations across the facility's units. The ...

Shares of Biocon have surged 44% in 2024 to date and 30% over the past two years, with the company currently holding a market ...

Insulin Biosimilar MarketThe global insulin biosimilar market is on track for significant expansion, with an estimated valuation of approximately USD 3,008.0 million in 2024. Exhibiting a year-on-year ...

Health portal Code Blue reported on Aug 21 that the ministry facilities nationwide were facing supply disruption of human ...

Biocon Biologics is focused on improving cash flows and increasing market shares of its biosimilar products, particularly in the US and Europe. The company is dealing with rising pricing pressure ...

Federal regulators are accusing the country's three largest pharmacy benefit managers of illegally driving up the cost of insulin in the U.S., while making it harder for patients to obtain cheaper ...

Biocon’s biosimilar foray began with a partnership with U.S.-based Mylan (now Viatris) for biosimilar monoclonal antibodies ...

In June 2019, Lija Greenseid handed Minnesota Gov. Tim Walz an empty vial of insulin that her 13-year-old daughter had painted gold. Greenseid's daughter has Type 1 diabetes, which means she ...

The Federal Trade Commission took action Friday against the nation’s three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted ...

The companies “artificially inflated the list price of insulin drugs, impaired patients’ access to lower list price products, and shifted the cost of high insulin list prices to vulnerable ...

medications, including insulin. UnitedHealth Group’s Optum Rx, CVS Health’s Caremark and Cigna’s Express Scripts have created a “perverse” drug rebate system that has “artificially ...